Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184785 | 0.85 | KDM4E (0.58) | SCN9AMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL184715 | 0.85 | AKR1C3 (0.57) | SCN9AMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL2734654 | 0.84 | NPC1 (0.46) | MAPK14CYP3A4PTGER4LIPGPTGER2 | |
| SCHEMBL15164048 | 0.81 | MAPK14 (0.54) | MAPK14CYP3A4SCN9APTGER4LIPG | |
| SCHEMBL20804634 | 0.81 | L3MBTL1 (0.70) | MAPK14CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL3031645 | 0.81 | MAPT (0.58) | MAPK14CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL12636178 | 0.80 | CYP3A4 (0.53) | MAPK14CYP3A4SCN9APTGER4LIPG | |
| SCHEMBL183373 | 0.80 | KDM4E (0.52) | SCN9APTGER4PTGER2MEN1KMT2A | |
| SCHEMBL6245709 | 0.79 | MEN1 (0.63) | MEN1KMT2AL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL4447484 | 0.79 | PTGER4 (0.65) | MAPK14CYP3A4PTGER4LIPGPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102112445-B | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors | BRISTOL MYERS SQUIBB CO | 2014-06-18 | — | — | CN | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| CN-102112445-A | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors | BRISTOL MYERS SQUIBB CO | 2011-06-29 | — | — | CN | disclosed |
| EP-2297103-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | MAPK14 1213/4885CYP3A4 3782/4885SCN9A 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.